Seems you have not registered as a member of localhost.saystem.shop!
You may have to register before you can download all our books and magazines, click the sign up button below to create a free account.
Systemic Treatment of Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Most patients present with advanced disease and five-year survival is low at about 15%. Surgery is the main treatment for early stage disease. If patients are deemed inoperable, systemic chemotherapy is considered. For patients with locally advanced disease, multimodality therapy is administered where chemotherapy is given incombination with definitive radiation therapy or surgery in selected cases. Cytotoxic chemotherapy regimens mainly con.
Principles of Molecular Oncology
At the midpoint of the 20th century, our knowledge of cancer was based on epide- ology and pathology, and treatment consisted of surgery and radiation therapy. At mid-century, Medawar and colleagues initiated the understanding of transplantation immunology, Farber described the first use of an antifolic drug to treat leukemia, and Jacobson and coworkers described the irradiation-protection effect of spleen cells. These observations opened the door to the development of chemotherapy and tra- plantation in the treatment of cancer. Despite the rapid development of these new disciplines, progress was usually based on empiric observations and clinical trials. The rapid advances in molecular biology at the end of the 20th century mark a new era in our knowledge of cancer. Molecular immunology, molecular genetics, mole- lar pharmacology, and the Human Genome Project are in the process of providing a level of understanding of cancer undreamed of in the past. Optimism is based on the firm belief that understanding at the molecular level will lead to better and earlier di- nosis, to new forms of treatment, and, most importantly, eventually to prevention of many types of cancer.
Targeted Therapies in Oncology, Second Edition
Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: Targeted agents of immune checkpoints Signal-transduction inhibitors Antiangiogenic agents Vascular-disrupting agents Apoptosis modulators Stem cell inhibitors Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world.
Tumor Angiogenesis
Themen dieses Bandes sind die molekularen Mechanismen der Tumor-Angiogenese, die Suche nach einschlägigen Targets für die Wirkstoffforschung und die Entwicklung von Kombinationstherapien mit bereits existierenden Ansätzen. Die ideale Informationsquelle für Studenten, Ärzte und Forscher in der Pharmaindustrie!
Systemic Treatment of Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Most patients present with advanced disease and five-year survival is low at about 15%. Surgery is the main treatment for early stage disease. If patients are deemed inoperable, systemic chemotherapy is considered. For patients with locally advanced disease, multimodality therapy is administered where chemotherapy is given in combination with definitive radiation therapy or surgery in selected cases. Cytotoxic chemotherapy regimens mainly consist of a platinum doublet. Biologic agents are increasingly being incorporated into treatment regi...
Internet of Things and Data Analytics Handbook
This book examines the Internet of Things (IoT) and Data Analytics from a technical, application, and business point of view. Internet of Things and Data Analytics Handbook describes essential technical knowledge, building blocks, processes, design principles, implementation, and marketing for IoT projects. It provides readers with knowledge in planning, designing, and implementing IoT projects. The book is written by experts on the subject matter, including international experts from nine countries in the consumer and enterprise fields of IoT. The text starts with an overview and anatomy of IoT, ecosystem of IoT, communication protocols, networking, and available hardware, both present and ...
Killer Algae
"This supposedly benign little plant - that no one thought could survive the waters of the Mediterranean - has become a pernicious force. Caulerpa taxifolia now covers 10,000 acres of the coasts of France, Spain, Italy, and Croatia, and has devastated Mediterranean ecosystems. And it continues to grow, unstoppable and toxic. When Alexandre Meinesz, a professor of biology at the University of Nice, learned of a square-yard patch of it in 1988, he warned biologists and oceanographers of the potential species invasion. His calls went unheeded. At that time, one person could have weeded the small patch and ended the problem. Since then, the plant has defeated the French Navy, thwarted scientific efforts to halt its rampage, and continues its destructive journey into the Adriatic Sea."--BOOK JACKET. "Killer Algae is the biological and political horror story of this invasion."--BOOK JACKET.
Textbook of Uncommon Cancer
Described as ‘must-have for cancer research’ by theHospital Doctor this highly acclaimed textbook has beenextensively revised and updated to reflect recent progress andunderstanding in the field. It is the only comprehensive source ofinformation available on uncommon cancers; presenting diagnosis,detailed clinical management and prognosis. The Textbook ofUncommon Cancer, Third Edition incorporated 18 newchapters, including: Tumors of the cervix Esthesioneuroblastoma Unusual malignancies of plasma cells Dermatofibrosarcoma protuberans Written by leading clinicians worldwide, this title isindispensable for all those involved in the diagnosis and treatmentof hard-to-manage rare tumors.
